Posts

Posted on

INVESTOR ALERT: monday.com Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

SAN DIEGO, March 21, 2026 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that the monday.com class action lawsuit – captioned Potter v. monday.com Ltd., No. 26-cv-01956 (S.D.N.Y.) – seeks to represent purchasers or acquirers of monday.com Ltd. (NASDAQ: MNDY) common stock and charges monday.com as well as certain of monday.com’s top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

monday.com

class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-monday-com-ltd-class-action-lawsuit-mndy.html

You can also contact attorney

J.C. Sanchez

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

. Lead plaintiff motions for the

monday.com

class action lawsuit must be filed with the court no later than May 11, 2026.

CASE ALLEGATIONS: monday.com, together with its subsidiaries, develops software applications.

The monday.com class action lawsuit alleges that defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to monday.com’s projected revenue outlook and anticipated growth on the back of its continued expansion of its core platform, AI-driven investments, increasing enterprise adoption and multi-product integration; (ii) monday.com was seeing new customer growth decelerating, weaker expansion within existing accounts and longer enterprise sales cycles, making monday.com’s $1.8 billion 2027 target increasingly unlikely to be met; and (iii) defendants misled investors by providing the public with materially flawed statements of confidence and growth projections which did not account for these variables.

The monday.com class action lawsuit further alleges that on February 9, 2026, monday.com disclosed that “we will no longer be discussing our previously provided 2027 targets, but we’ll be centering our discussion on our 2026 outlook, which reflects the continued momentum we see across our AI work platform, new product introductions and upmarket sales motion.” On this news, the price of monday.com stock fell nearly 21%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired monday.com common stock during the class period to seek appointment as lead plaintiff in the monday.com class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the monday.com investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the monday.com shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the monday.com class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]



Posted on

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

SEATTLE–(BUSINESS WIRE)–
Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm – 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,” will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôpital Saint-Antoine, AP-HP, and will feature speakers Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, and Michelle L. Schoettler, MD, MS, Children’s Healthcare of Atlanta.

The EBMT Annual Meeting is a key event for professionals in transplantation and cellular therapy, bringing together stakeholders from around the world.

About Omeros Corporation

Omeros is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros’ lead lectin pathway inhibitor YARTEMLEA® (narsoplimab-wuug), which inhibits the pathway’s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. A marketing authorization application for YARTEMLEA in TA-TMA is currently under review at the European Medicines Agency. OMS1029, Omeros’ long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.

Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder that is fully funded by the National Institute on Drug Abuse, as well as a growing portfolio of novel molecular and cellular oncology programs. For more information about Omeros and its programs, visit www.omeros.com.

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

[email protected]

KEYWORDS: Washington Europe Spain United States North America

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo
Logo
Posted on

INVESTOR ALERT: Gartner, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that the Gartner class action lawsuit – captioned Schmidt v. Gartner, Inc., No. 26-cv-00394 (D. Conn.) – seeks to represent purchasers or acquirers of Gartner, Inc. (NYSE: IT) common stock and charges Gartner and certain of Gartner’s executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

Gartner

class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-gartner-inc-class-action-lawsuit-it.html

You can also contact attorney

J.C. Sanchez

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

. Lead plaintiff motions for the

Gartner

class action lawsuit must be filed with the court no later than May 18, 2026.

CASE ALLEGATIONS: Gartner provides business and technology insights for decisions and performance on an organization’s mission-critical priorities.

The Gartner class action lawsuit alleges that defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to Gartner’s contract value (“CV”) growth potential and projected Consulting segment revenue outlook while also minimizing risk from seasonality and macroeconomic fluctuations; (ii) defendants highlighted that the environment among “tariff impacted companies” was “starting to improve,” generating “more certainty” in the demographics, which allegedly would result in the opportunity for continued CV growth for Gartner; and (iii) while tariff impacts continued to ease and settle and companies were acting with more certainty, Gartner’s non-federal CV growth would fall even further as its Consulting segment revenue faltered below Gartner’s long-held projections.

The Gartner class action lawsuit further alleges that on August 5, 2025, Gartner announced its second quarter fiscal 2025 earnings, revealing that its overall CV growth declined from 7% the previous quarter to only 5%; and, the ex-federal CV growth declined from 8% the previous quarter to merely 6%. On this news, the price of Gartner stock fell more than 27%, according to the complaint.

Then, on February 3, 2026, the Gartner class action lawsuit alleges that Gartner announced a significant decline in its CV growth rate, which had faltered another 2% including and excluding federal contracts, and for the first time disclosed a significant shortfall of its Consulting segment’s performance against Gartner’s internal projections. On this news, the price of Gartner stock fell nearly 21%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Gartner common stock during the class period to seek appointment as lead plaintiff in the Gartner class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Gartner investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Gartner shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Gartner class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]



Posted on

Fortinet Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortinet Inc. – FTNT

Fortinet Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortinet Inc. – FTNT

NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fortinet Inc. (the “Company”) (NasdaqGS: FTNT).

On August 6, 2025, the Company disclosed disappointing second-quarter 2025 financial results, including that it was already “approximately 40% to 50% of the way through the 2026 upgrade cycle at the end of the second quarter [of 2025] based on the remaining active units and service contracts,” that excess [firewall] capacity by customers meant less demand for upgrades, and also issued weaker-than-expected revenue guidance for the upcoming third quarter, projecting revenue between $1.67 billion and $1.73 billion.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.

KSF’s investigation is focusing on whether Fortinet’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Fortinet shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ftnt/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-877-515-1850

KEYWORDS: United States North America Louisiana New York

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

Gartner, Inc. Securities Fraud Class Action Result of Reduced Guidance Disclosure and 48% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Gartner, Inc. Securities Fraud Class Action Result of Reduced Guidance Disclosure and 48% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have untilMay 18, 2026 to file lead plaintiff applications in a securities class action lawsuit against Gartner, Inc. (NYSE: IT) (“Gartner” or the “Company”), if they purchased or otherwise acquired the Company’s shares between February 4, 2025, and February 2, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Connecticut.

What You May Do

If you purchased shares of Gartner and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-it/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 18, 2026.

About the Lawsuit

Gartner and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 5, 2025, the Company announced its 2Q 2025 results, disclosing that overall contract value (“CV”) growth declined from 7% the previous quarter to only 5%, and ex-federal CV growth declined from 8% the previous quarter to only 6%. On this news, the price of Gartner’s shares fell from a closing price of $336.71 per share on August 4, 2025, to $243.93 per share on August 5, 2025, a decline of about 27.55% in the span of just a single day.

Then, on February 3, 2026, the Company disclosed that its CV growth rate had continued to decline another 2% both including and excluding federal contracts, and for the first time disclosed a significant shortfall of its Consulting segment’s performance against the Company’s internal projections. On this news, the price of Gartner’s shares fell from a closing price of $202.40 per share on February 2, 2026, to $160.16 per share on February 3, 2026, a decline of nearly 20.87% in the span of one day.

The case is Schmidt v. Gartner, Inc., No. 26-cv-00394.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner

[email protected]

1-877-515-1850

1100 Poydras St., Suite 960

New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

KEYWORDS: United States North America Connecticut New York Louisiana

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo
Posted on

Oxbridge Re Announces 2025 Fourth Quarter Results on March 30, 2026

GRAND CAYMAN, Cayman Islands, March 20, 2026 (GLOBE NEWSWIRE) — Oxbridge Re Holdings Limited (NASDAQ: OXBR), (the “Company”), which together with its subsidiaries is engaged in the business of tokenized Real-World Assets (“RWAs”), initially in the form of tokenized reinsurance securities, and reinsurance business solutions to property and casualty today, announced that it plans to hold a conference call on Monday March 30, 2026 at 4:30 p.m. Eastern time to discuss results for the fourth quarter and year ending December 31, 2025. Financial results will be issued in a press release after the close of the market on the same day. Oxbridge Re’s management will host the conference call, followed by a question and answer period.

Interested parties can listen to the live presentation by dialing the listen-only number below.

Date: March 30, 2026
Time: 4:30 p.m. Eastern time
Listen-only toll-free number: 877 524-8416
Listen-only international number: +1 412 902-1028
 

Please call the conference telephone number 10 minutes before the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact InComm Conferencing at +1-201-493-6280

A replay of the call will be available by telephone after 4:30 p.m. Eastern time on the same day of the call until April 13, 2026.

Toll-free replay number: 877-660-6853
International replay number: +1 201-612-7415
Replay passcode: 13759252
 

About Oxbridge Re Holdings Limited


Oxbridge Re Holdings Limited
 (NASDAQ: OXBR, OXBRW) (“Oxbridge Re”) is headquartered in the Cayman Islands. The company offers tokenized Real-World Assets (“RWAs”) as tokenized reinsurance securities and reinsurance business solutions to property and casualty insurers, through its subsidiaries SurancePlus Inc, Oxbridge Re NS, and Oxbridge Reinsurance Limited.

Insurance businesses in the Gulf Coast region of the United States purchase property and casualty reinsurance through our licensed reinsurers Oxbridge Reinsurance Limited and Oxbridge Re NS.

Our Web3-focused subsidiary, SurancePlus Inc., has developed the first “on-chain” reinsurance RWA of its kind to be sponsored by a subsidiary of a publicly traded company. By digitizing interests in reinsurance contracts as on-chain RWAs, SurancePlus has democratized the availability of reinsurance as an alternative investment to both U.S. and non-U.S. investors.

Company Contact:
Oxbridge Re Holdings Limited
Jay Madhu, CEO
+1 345-749-7570
[email protected]



Posted on

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, March 20, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that it has closed an initial tranche (“First Tranche”) of the offering announced on March 10, 2026 and March 11, 2026 (collectively, the “Announcement NRs”) and has issued 3,750 Debenture Units (as defined in the Announcement NRs) for $3,750,000.

The Company will use the proceeds from the First Tranche for the ongoing development of the Company’s business model and for general working capital purposes.

One director of the Company (the “Director Subscriber”) participated in the Offering (as defined in the Announcement NRs) and subscribed for Debenture Units representing aggregate gross proceeds of $300,000. The participation by the Director Subscriber in the Offering constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction exceeds 25% of the Company’s market capitalization, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party aspects of the Director Subscriber’s participation in the Offering at least 21 days before the closing of the Offering, which the Company deems reasonable in the circumstances in order to expedite the completion of the Offering.

Debt Settlement

In addition, the Company has completed an initial batch of the Debt Settlement (as defined in the Announcement NRs) by issuing an aggregate of 370,457 Class B subordinate voting shares in the Company (each, a “Class B Share”) to settle approximately $1,117,727 of debt owed to certain arm’s length creditors and insiders of the Company.

The participation by insiders of the Company in the Debt Settlement constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction exceeds 25% of the Company’s market capitalization, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party aspects of the Debt Settlement at least 21 days before the closing of the Debt Settlement, which the Company deems reasonable in the circumstances in order to expedite the completion of the Debt Settlement.

All amounts in this press release are expressed in Canadian dollars.

The securities described herein have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, Quantum BioPharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses.

Forward-Looking Information

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements relating to: the closing of the Offering and the Debt Settlement; the use of proceeds from the Offering; and the Shares issued pursuant to the Debt Settlement, and potential issuance of Shares and Debenture Units.

Forward-looking information in this press release is based on certain assumptions and expected future events, including but not limited to: the Company has the ability to complete additional tranches of the Offering and the Debt Settlement.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: risks relating to the Company’s business and operations generally; and the reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Contacts:

Quantum BioPharma Ltd.

Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: [email protected]
Telephone: (416) 854-8884

Investor Relations
Email: [email protected], [email protected]
Website: www.quantumbiopharma.com



Posted on

SMCI INVESTIGATION ALERT: Investigation Launched into Super Micro Computer, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm – RGRD Law

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP is investigating potential violations of the U.S. securities law involving Super Micro Computer, Inc. (NASDAQ: SMCI).

If you have information that could assist in the Super Micro investigation or if you are a Super Micro investor who suffered a loss and would like to learn more, you can provide your information here:


https://www.rgrdlaw.com/cases-super-micro-computer-investigate-smci.html

You can also contact attorneys

Ken Dolitsky

or

Michael Albert

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

.

THE COMPANY: Super Micro develops and manufactures high performance server and storage solutions.

THE REVELATION: On March 19, 2026, Super Micro announced that it “was informed today that the United States Attorney’s Office for the Southern District of New York has unsealed an indictment of three individuals associated with the Company in connection with an alleged conspiracy to commit export-control violations.” On this news, the price of Super Micro stock fell more than 33%.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        Ken Dolitsky
        Michael Albert
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]



Posted on

Union Pacific Celebrates America’s 250th Anniversarywith New Locomotives No. 4547 and No. 1776

Union Pacific Celebrates America’s 250th Anniversarywith New Locomotives No. 4547 and No. 1776

Historic Big Boy No. 4014 Steam Locomotive to Tour the East Coast

OMAHA, Neb.–(BUSINESS WIRE)–
Union Pacific Railroad, founded by President Abraham Lincoln in 1862, unveiled its plans today to celebrate the United States, its amazing history and the people behind its unparalleled success story with two new locomotives and the first Big Boy steam tour to the East Coast in honor of America’s 250th anniversary.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320244683/en/

Union Pacific's newest commemorative locomotive: No. 4547

Union Pacific’s newest commemorative locomotive: No. 4547

Big Boy, the world’s largest operating steam locomotive, will journey to Philadelphia for Fourth of July, with stops planned in Illinois, Indiana, Ohio, New York and Pennsylvania.

Our nation’s origin will be celebrated with a beautiful No. 1776 – America250 locomotive that will feature an American flag waving against the backdrop of a traditional, armor-yellow Union Pacific locomotive and the America250 logo. President Lincoln, our founder, is commemorated with the No. 1616 locomotive in a paint scheme characteristic of his era.

Our third and newest commemorative locomotive No. 4547 was built in partnership with Wabtec. It celebrates our current president, President Donald J. Trump and features large, flowing American flags on each side of the locomotive, one with 13 stars for the original colonies and the other depicting today’s beloved red, white and blue flag.

This is the third in a series of presidential locomotives, which also includes the No. 4141, the locomotive that honors the late President George H.W. Bush, and that allowed our proud Union Pacific employees to transport the late president to his final resting place in College Station, Texas, where the locomotive is now on display at the George Bush Presidential Library and Museum.

“Union Pacific is honored to take part in the 250th anniversary of this great nation,” said Union Pacific CEO Jim Vena. “Each of these commemorative locomotives symbolizes important moments in the history of Union Pacific and the U.S. Our shared history shows the vital role railroads have played and will continue to play for generations to come.”

The Big Boy will leave Cheyenne, Wyoming, March 29 for the first leg of its historic tour, returning April 24, after making stops in California, Nevada, Utah and Wyoming.

The Eastern leg begins May 25 and will include display days in Omaha, Nebraska; Chicago, Illinois; Buffalo, New York; and Scranton, Pennsylvania, before Big Boy’s arrival in Philadelphia for Independence Day. Additional display days are anticipated in Altoona, Pennsylvania, and St. Louis and Kansas City, Missouri, before the tour concludes July 29.

A detailed schedule for the East Coast leg, including whistlestop locations, will be released at a later date. Anyone interested in learning more is invited to join Union Pacific’s Steam Club at upsteam.com.

ABOUT UNION PACIFIC

Union Pacific (NYSE: UNP) delivers the goods families and businesses use every day with safe, reliable and efficient service. Operating in 23 western states, the company connects its customers and communities to the global economy. Trains are the most environmentally responsible way to move freight, helping Union Pacific protect future generations. More information about Union Pacific is available at www.up.com.

Union Pacific Media Contact: Kristen South at [email protected]

www.up.com

www.facebook.com/unionpacific

www.twitter.com/unionpacific

KEYWORDS: United States North America Nebraska

INDUSTRY KEYWORDS: Rail Transport Logistics/Supply Chain Management Other Transport

MEDIA:

Logo
Logo
Photo
Photo
Union Pacific’s newest commemorative locomotive: No. 4547
Logo
Logo
Posted on

Volato Announces Receipt of Continued Listing Standards Notice From NYSE American

Volato Announces Receipt of Continued Listing Standards Notice From NYSE American

 

ATLANTA–(BUSINESS WIRE)–
Volato Group, Inc. (the “Company” or “Volato”) (NYSE American: SOAR) today announced that on March 17, 2026, it received a notice (the “notice”) from the NYSE American LLC (the “NYSE American”) advising the Company that it is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years and Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Company must submit a plan (the “Plan”) by April 16, 2026 to the NYSE American outlining actions it has taken or will take to regain compliance with the continued listing standards by December 17, 2026. If the Plan is not permitted or the Plan is not accepted, delisting proceedings will commence.

The notice has no immediate impact on the listing of Volato’s shares of common stock on the NYSE American. Volato’s common stock will continue to be listed and traded on the NYSE American under the ticker “SOAR”, during the nine-month period allotted for the Company to regain compliance, subject to the Company’s compliance with the other continued listing standards of the NYSE American.

The notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission (the “SEC”).

Volato is committed to regaining compliance with the NYSE American’s continued listing standards but cannot guarantee that it will regain compliance within the allotted period of time.

Also, as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, the independent registered public accounting firm’s report includes an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern. This paragraph does not represent a qualification, adverse opinion, or disclaimer of opinion, and the Company’s consolidated financial statements have been prepared in accordance with U.S. GAAP. Release of this information is required by Section 610(b) of the NYSE American Company Guide. It does not represent any change or amendment to any of the Company’s filings for the fiscal year ended December 31, 2025.

About Volato

Volato Group, Inc. (NYSE American: SOAR) is a technology company focused on building scalable software and data solutions that improve the reliability and intelligence of high-stakes business decisions. The Company’s existing Parslee Document Intelligence platform enhances the performance of leading large language models (LLMs) by adding deterministic structure and auditability to complex documents such as contracts and SEC filings. Through its proposed merger with M2i Global, Inc., Volato is expanding into the critical minerals sector—leveraging its software expertise to bring greater transparency, traceability, and operational intelligence to supply chains essential for U.S. national security and advanced technologies. For more information visit www.flyvolato.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the securities laws. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words or variation of words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “targets,” “would,” “will,” “should,” “goal,” “could” or “may” or other similar expressions. Forward-looking statements provide management or the board’s current expectations or predictions of future conditions, events, or results. All statements that address operating performance, events, or developments that may occur in the future are forward-looking statements, including statements regarding the challenges associated with executing our growth strategy, developing, marketing and consistently delivering high-quality services that meet customer expectations. All forward-looking statements speak only as of the date they are made and reflect the Company’s good faith beliefs, assumptions, and expectations, but they are not guarantees of future performance or events. Furthermore, Volato disclaims any obligation to publicly update or revise any forward-looking statement, except as required by law. By their nature, forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Factors that might cause such differences include, but are not limited to, a variety of economic, competitive, and regulatory factors, many of which are beyond Volato’s control, that are described in Volato’s periodic reports filed with the SEC including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, subsequent reports filed with the SEC, and other factors that Volato may describe from time to time in other filings with the SEC. You should understand that it is not possible to predict or identify all such factors and, consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

For Investors:

[email protected]

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Technology Air Transport Software Networks Transportation Data Management Travel Artificial Intelligence

MEDIA: